Search company, investor...

Kantum Pharma

Submit Your Analyst Briefing

kantumpharma.com

Founded Year

2016

Stage

Series A | Alive

Total Raised

$6.73M

Last Raised

$3.53M | 1 yr ago

About Kantum Pharma

Kantum is developing a specific AKI therapy to help critical care clinicians prevent hundreds of thousands of deaths from AKI. This targeted therapy will be supported by the development of a diagnostic test for AKI.

Headquarters Location

75 S Main St #7-160

Concord, New Hampshire, 03301,

United States

Missing: Kantum Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Kantum Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Kantum Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kantum Pharma is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

8,493 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,901 items

Kantum Pharma Patents

Kantum Pharma has filed 4 patents.

The 3 most popular patent topics include:

  • Dopamine agonists
  • EC 2.4.1
  • Kidney diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/16/2019

EC 2.4.1, Cardiac surgery, Dopamine agonists, Kidney diseases, Enzymes of unknown structure

Application

Application Date

4/16/2019

Grant Date

Title

Related Topics

EC 2.4.1, Cardiac surgery, Dopamine agonists, Kidney diseases, Enzymes of unknown structure

Status

Application

Latest Kantum Pharma News

11:30 EDT Acute Kidney Injury Market to Grow at a CAGR of Approximately 8% by 2032 | DelveInsight

Jun 21, 2022

| DelveInsight News provided by Share this article Share this article The dynamics of acute kidney injury market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world and the expected launch of the emerging therapies during the forecast period. LAS VEGAS, June 21, 2022 /PRNewswire/ -- DelveInsight's Acute Kidney Injury Market Insights report includes a comprehensive understanding of current treatment practices, Acute Kidney Injury emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan. Key Takeaways from the Acute Kidney Injury Market Report As per DelveInsight analysis, the Acute Kidney Injury market size in the 7MM was approximately USD 5.4 billion in 2020. As per DelveInsight analysis, the total Acute Kidney Injury incident cases in the 7MM were approximately 10.9 million in 2020. The United States contributed to the largest incident-patient share (mortality adjusted), acquiring ~ 34.09% of the 7MM in 2020 Rising incidence of AKI will provide a larger window of opportunity for new treatment and prevention options The pipeline of AKI is quite robust with diverse products strengthening targeting prophylaxis of AKI in several complications such as Sepsis and post-cardiac-surgery mainlyLeading acute kidney injury companies such as Cerenis Therapeutics, Alloksys, Vifor Pharma, Exponential Biotherapies, Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, Nephraegis Therapeutics, Vasomune, Unicycive, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Astellas Pharma, Amniotics, Mission Therapeutics, Bessor pharma, Kantum Pharma, ABIONYX, and others are developing novel drug candidates to improve the Acute Kidney Injury treatment landscape. The Acute Kidney Injury therapies in the pipeline include bRESCAP, ANG-3777, EA-230, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), and others. The key driver for the surge in acute kidney injury market size is the rise in the number of incident cases of acute kidney injury. Discover more about therapies set to grab major acute kidney injury market share @  Acute Kidney Injury Market Landscape Acute Kidney Injury Overview Acute kidney injury (AKI), also known as acute renal failure (ARF), is a disorder that causes progressive azotemia with or without oliguria over a period of hours or days. Acute kidney injury is defined as a sudden loss of renal function, clinically expressed as an acute reversible surge in nitrogen waste products as measured by blood urea nitrogen and serum creatinine levels over hours to weeks. Acute kidney injury causes an abrupt loss in renal function, which results in waste product retention, electrolyte abnormalities, and changes in volume status. Acute kidney injury is classified into prerenal, postrenal, and intrinsic renal. Many people with acute kidney injury are asymptomatic, while others experience generalized non-specific acute kidney injury symptoms such as nausea, vomiting, weakness, dizziness, lower back pain, passing less urine than usual, unexplained loss of appetite, feeling sick or vomiting, shortness of breath, and swelling of the legs or other body parts. An increase in serum creatinine and a reduction in urine output are commonly used for acute kidney injury diagnosis. Acute Kidney Injury Epidemiology Segmentation As per DelveInsight, there were approx 10.9 million acute kidney injury incident cases  in the 7MM in 2020. Among the EU5 countries, Germany had the highest acute kidney injury incident population in 2020. The Acute Kidney Injury market report  proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into Total Incident Population of Acute Kidney Injury (AKI) in Hospitalized Patients Mortality Adjusted Incident Population of AKI in Hospitalized Patients Stage-specific Incident Population of AKI Age-specific Incident Population of AKI Download the report to understand which factors are driving acute kidney injury epidemiology trends @ Acute Kidney Injury Epidemiological Insights Acute Kidney Injury Treatment Market  For the past several years; it has been observed that the current acute kidney injury treatment is primarily supportive in character, with no therapeutic approaches demonstrating benefit in treating the condition. Off-label acute kidney injury medications used to treat AKI include ACE inhibitors, angiotensin II-receptor blockers (ARBs), diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), and renal replacement therapy (RRT). Monitoring urine output and, at first, serum creatinine levels (SCr) numerous times each day is a cornerstone of the therapy for all patients with acute kidney injury. It is also indicated to correct electrolyte imbalances, quit or adjust nephrotoxic medicines, and dose-adjust pharmaceuticals with renal elimination. To know more about Acute Kidney Injury treatment, visit @ Acute Kidney Injury Guidelines Acute Kidney Injury Pipeline Therapies and Key Companies bRESCAP: Alloksys EA-230: Exponential Biotherapies Treatment-related adverse effects are quite rare, resulting in successful acute kidney injury treatment choices. Moreover, patients have easy access to reimbursements since their ailment necessitates long-term management, such as dialysis. In addition, several government activities are being undertaken by adopting various programs concerning acute kidney injury, which is expected to improve the global AKI prospect and thus bolster the actue kidney injury market. Furthermore, several biomarkers, including NGAL, Cystatin-C, and others, are being investigated for use in acute kidney injury diagnosis. The validation of these new biomarkers could provide new methods for detecting the start and severity of kidney injury. Future research in the acute kidney injury market is underway with the goal of better understanding of the underlying processes and, as a result, improve outcomes for AKI patients. Moreover, a robust pipeline with a novel mechanism of action and increasing incidence are major market drivers of the acute kidney injury market. Additionally, the acute kidney injury pipeline is also expected to change the current dynamics of the acute kidney injury market, which presently comprises biologics and molecules with new mechanisms of action like ANG-3777 (BB3), ASP1128, Ilofotase alfa, Ruconest (Conestat alfa), bRESCAP, EA230, and others. However, there are several barriers to the acute kidney injury market growth. One such factor is the lack of awareness. If the patients have cardiac issues, the situation becomes even more complex. Moreover, long-term health repercussions, as well as longer hospital stays and high health-care expenses, highlight AKI's enormous societal impact. In addition, several risk factors, such as diabetes and heart failure, have substantial implications for patients' quality of life, making it challenging to develop promising future interventions and thus hindering the acute kidney injury market growth. Scope of the Acute Kidney Injury Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Acute Kidney Injury Companies: Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, Nephraegis Therapeutics, Vasomune, Unicycive, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Astellas Pharma, Amniotics, Mission Therapeutics, Bessor pharma, Kantum Pharma, ABIONYX, and others Key Acute Kidney Injury Therapies: bRESCAP, ANG-3777, EA-230, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), and others Therapeutic Assessment: Acute kidney injury current marketed and emerging therapies Acute Kidney Injury Market Dynamics: Acute kidney injury market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Acute Kidney Injury Market Access and Reimbursement Table of Contents Chronic Kidney Disease Pipeline Insight, 2022 report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key chronic kidney disease companies, including Bayer, AstraZeneca, Celgene, Ipsen, among others. Anemia in Chronic Kidney Disease Pipeline Insight, 2022 report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key anemia in chronic kidney disease companies, including Pieris Pharmaceuticals, Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, among others. Polycystic Kidney Disease Pipeline Insight, 2022 report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key anemia in polycystic kidney disease companies, including Abbott, Reata Pharmaceuticals, XORTX Therapeutics, Sanofi Genzyme, among others. Kidney Transplant Rejection Pipeline Insight, 2022 report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key anemia in kidney transplant rejection companies, including Medeor Therapeutics, Talaris Therapeutics, CSL Behring, Novartis, among others. Other Trending Reports

Kantum Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Kantum Pharma Rank

Kantum Pharma Frequently Asked Questions (FAQ)

  • When was Kantum Pharma founded?

    Kantum Pharma was founded in 2016.

  • Where is Kantum Pharma's headquarters?

    Kantum Pharma's headquarters is located at 75 S Main St #7-160, Concord.

  • What is Kantum Pharma's latest funding round?

    Kantum Pharma's latest funding round is Series A.

  • How much did Kantum Pharma raise?

    Kantum Pharma raised a total of $6.73M.

  • Who are the investors of Kantum Pharma?

    Investors of Kantum Pharma include Broadview Ventures, 10X Venture Partners, New Hampshire Tech Alliance and Mill Works Fund.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.